Myelofibrosis

Learn more about the newest discoveries and latest clinical insights in myelofibrosis (MF). Cancer Nursing Today provides up-to-date perspectives and information on transplant trends in MF, novel therapeutic targets, and more. From promising new treatments to risk factors and prognostics, explore the latest developments in MF care.

How Momelotinib Affects Survival Outcomes in Myelofibrosis
Momelotinib prolonged overall survival (OS) and leukemia-free survival (LFS) in patients with myelofibrosis compared with danazol, an exploratory analysis of the MOMENTUM trial showed. The phase III study evaluated momelotinib, a Janus kinase (JAK) inhibitor, versus danazol, a pituitary gonadotropin inhibitor that is approved to treat anemia in myelofibrosis. The study included 195 patients who had myelofibrosis, anemia, and splenomegaly. At week 24, all patients who had received momelotinib showed spleen, symptom, and anemia ...
Advertisement
Advertisement

Knowledge Hubs

Breast Cancer
Breast Cancer

Trending

Advertisement
Advertisement
Latest News